CanBas Co.,Ltd.

4575 TSE Pharmaceutical PHARMACEUTICAL

Key Metrics

Market Cap

14.7B ($92.6M)

P/E Ratio

N/A

P/B Ratio

N/A

Revenue

N/A

Net Income

-1.2B

Gross Margin

N/A

Op. Margin

N/A

Net Margin

N/A

ROE

-39.3%

ROA

-38.0%

D/E

0.04

Dividend Yield

N/A

EPS

-61.14

Current Ratio

27.67

Price History

Company Info

Industry	PHARMACEUTICAL
Market Segment	Growth
Accounting	Japan GAAP
Currency	JPY
Fiscal Year	2025

Business Overview

CanBas Co., Ltd., a clinical stage biopharmaceutical company, engages in the basic research and clinical development of anti-cancer drugs. It develops CBP501, a compound which regulates the regulatory function of the protein calmodulin in Phase 2 clinical trials targeting non-small cell lung cancer; and CBS9106 for patients with advanced solid tumors. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.

Full Financials Advanced Charts Filings

Peers

Takeda Pharmaceutical Company Limited

4502

9.1T

P/E: 81.3

Astellas Pharma Inc.

4503

4.3T

P/E: 34.2

Shionogi & Co.,Ltd.

4507

2.9T

P/E: 16.8

Kyowa Kirin Co.,Ltd.

4151

1.2T

P/E: 18.3

Sumitomo Pharma Co.,Ltd.

4506

736.8B

P/E: 4.8

SANTEN PHARMACEUTICAL CO.,LTD.

4536

542.5B

P/E: 18.2

Nippon Shinyaku Co.,Ltd.

4516

337.9B

P/E: 10.6

GNI Group Ltd.

2160

158.0B

P/E: --

Financial Statements

Loading financials...

Open Advanced Charts

Full charting with technical indicators, candlestick, and more.

About CanBas Co.,Ltd.

Ticker	4575
Exchange	TSE
Sector	Pharmaceutical
Industry	PHARMACEUTICAL